{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:44:48Z","timestamp":1728175488758},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T00:00:00Z","timestamp":1395100800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s00702-014-1165-7","type":"journal-article","created":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T01:55:02Z","timestamp":1395107702000},"page":"769-771","source":"Crossref","is-referenced-by-count":11,"title":["IncobotulinumtoxinA (Xeomin\u00ae) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport\u00ae)"],"prefix":"10.1007","volume":"121","author":[{"given":"Dirk","family":"Dressler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fereshte","family":"Adib Saberi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Bigalke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,18]]},"reference":[{"issue":"Suppl 2","key":"1165_CR1","first-page":"S227","volume":"25","author":"SF Adib","year":"2010","unstructured":"Adib SF, Bigalke H, Dressler D (2010) Antigenicity differences between botulinum toxin drugs. Mov Disord 25(Suppl 2):S227 (Abstract)","journal-title":"Mov Disord"},{"key":"1165_CR2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000064953","volume":"48","author":"D Dressler","year":"2002","unstructured":"Dressler D (2002) Clinical features of secondary failure of botulinum toxin therapy. Eur Neurol 48:26\u201329","journal-title":"Eur Neurol"},{"key":"1165_CR3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1468-1331.2011.03559.x","volume":"19","author":"D Dressler","year":"2012","unstructured":"Dressler D (2012) Five-year experience with incobotulinumtoxinA (Xeomin\u00ae): the first botulinum toxin drug free of complexing proteins. Eur J Neurol 19:385\u2013389","journal-title":"Eur J Neurol"},{"key":"1165_CR4","volume-title":"Manual of botulinum toxin therapy","author":"D Dressler","year":"2009","unstructured":"Dressler D, Bigalke H (2009) Pharmacology of botulinum toxin drugs. In: Truong D, Dressler D, Hallett M (eds) Manual of botulinum toxin therapy. Cambridge University Press, Cambridge"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-014-1165-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-014-1165-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-014-1165-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:30:27Z","timestamp":1559089827000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-014-1165-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,18]]},"references-count":4,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["1165"],"URL":"https:\/\/doi.org\/10.1007\/s00702-014-1165-7","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,18]]}}}